|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS, GB
|
|
Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by two clinical-stage programs, NG-350A and NG-641; both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI) To learn more, please visit www.akamisbio.com.
|
Akamis Bio Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Akamis Bio email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Akamis Bio customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.